RxDoctor Payments Data

Munish Shastri, MD

Internal Medicine · Bloomfield, CTNPI 1649280538

Payments from drug & device makers

$733in general payments, 2019–2025

Across 45 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$150
  • AstraZeneca$68
  • Johnson & Johnson$59
  • Novo Nordisk$58
  • Pfizer$53
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$51
  • plus $295 from 12 others

What the payments were for

  • Food & beverage$733100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$733 in reported general payments places this provider in the 70th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$79,050
Medicare patients
305
Services billed
1,935

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide183$357,795
JardianceEmpagliflozin226$323,375
JanuviaSitagliptin Phosphate111$119,971
FarxigaDapagliflozin Propanediol81$106,488
EliquisApixaban76$94,441
TrulicityDulaglutide42$88,786
PercocetOxycodone Hcl/Acetaminophen15$80,174
XareltoRivaroxaban64$78,597
MyrbetriqMirabegron63$50,727
LinzessLinaclotide40$37,682
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$36,555
JanumetSitagliptin Phos/Metformin Hcl22$28,406
ProliaDenosumab15$26,431
Bydureon BciseExenatide Microspheres14$17,448
OxycontinOxycodone Hcl11$8,072

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$58$357,795183 claims
MerckJanuvia, Janumet$12$148,377133 claims
AstraZenecaFarxiga, Symbicort$68$111,92599 claims
PfizerEliquis$53$94,44176 claims
Lilly USA, LLCTrulicity$43$88,78642 claims
Johnson & JohnsonXarelto$59$78,59764 claims
Astellas Pharma US IncMyrbetriq$24$50,72763 claims
GSKTrelegy Ellipta$32$36,55534 claims
AmgenProlia$150$26,43115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Bloomfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →